CEVIMELINE HYDROCHLORIDE (cevimeline hydrochloride) by Hikma is clinical pharmacology pharmacodynamics cevimeline is a cholinergic agonist which binds to muscarinic receptors. Approved for symptoms of dry mouth in patients with sjögren's syndrome. First approved in 2013.
Drug data last refreshed 20h ago
CLINICAL PHARMACOLOGY Pharmacodynamics Cevimeline is a cholinergic agonist which binds to muscarinic receptors. Muscarinic agonists in sufficient dosage can increase secretion of exocrine glands, such as salivary and sweat glands and increase tone of the smooth muscle in the gastrointestinal and…
Worked on CEVIMELINE HYDROCHLORIDE at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.